共 83 条
[1]
Chen C(2013)Evaluating use characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer J Oncol Pract 9 182-187
[2]
Dhanda R(2001)National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000 J Natl Cancer Inst 93 979-989
[3]
Tseng WY(2003)Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357-3365
[4]
Eifel P(2006)Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview Ann Oncol 17 x59-x62
[5]
Axelson JA(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826
[6]
Costa J(2006)A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 R25-3734
[7]
Goldhirsch A(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-1150
[8]
Wood WC(2016)American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 1134-354
[9]
Gelber RD(2016)Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Cancer Netw 14 324-728
[10]
Clarke M(2008)Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 721-e45s